ClinicalTrials.gg
CompletedNCT05232929WeSMAUpdated Oct 22, 2026

Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)

A Phase 4 interventional study of Risdiplam in Spinal Muscular Atrophy, sponsored by Genentech, Inc.. Completed at 38 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 4, Interventional, and Treatment

How we know

Updated Oct 22, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
403
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing risdiplam in Muscular Atrophy, Spinal — none open to participants now, 4 under way, none of them phase 3. Risdiplam · Muscular Atrophy, Spinal.

Enrollment
Largest of 13
403 · median 33
Started
2022
with 1 other
Phase 4
4 of 13
none open now
Registered
9th of 13
by date
Lead sponsor
1 of 13
Genentech, Inc.

Among the 13 studies testing risdiplam in Muscular Atrophy, Spinal, this one has the largest enrollment, is one of 2 that started in 2022, is one of 4 in phase 4, and was the 9th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

None of the 13 studies testing risdiplam in Muscular Atrophy, Spinal is open now. The open studies under Muscular Atrophy, Spinal, anywhere →

About risdiplam

Risdiplam: first FDA approval 2020 (EVRYSDI), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing risdiplam in Muscular Atrophy, Spinal as a file.
02

Study summary

A multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Information (USPI) in adult and pediatric participants with SMA. In this study, participants will be followed for approximately 24 months from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study if they agree to continue participating in the follow-up assessments.

An optional sub-study was planned to assess the feasibility, acceptability, and adherence of remote assessment of motor and bulbar functions in participants with SMA using wearable and smartphone-based biosensors. This substudy was withdrawn upon implementation of protocol version 4.

03

Conditions studied

  • Spinal Muscular Atrophy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide or assent when appropriate, as determined by the participant's age and individual site and local standards
  • Prescribed or continued risdiplam based on clinical judgment of prescriber, as per the risdiplam (Evrysdi) USPI, after U.S. FDA approval (07 August 2020)

Exclusion criteria

Exclusion Criteria:

  • to risdiplam
  • Participated in a registrational trial for risdiplam (i.e., Firefish [NCT02913482], Sunfish [NCT02908685], Jewelfish [NCT03032172], and Rainbowfish [NCT03779334])
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
403 participants (actual)

Study arms

  • Experimental
    Risdiplam

    Participants who are taking risdiplam prescribed based on clinician judgment, as per the Evrysdi® USPI are enrolled in this study. A Remote Virtual Site option is available in the study allowing enrollment of participants with SMA who are prescribed risdiplam treatment even if their physician is not a participating investigator. A central investigator will be responsible for data collection and data entry for participants who do not have a participating investigator.

    Drug: Risdiplam

Interventions

  • Risdiplam taken by participants as prescribed by their physician.

    Also known as: Evrysdi®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as AE.

    Time frame: From enrollment up to the duration of the study or until withdrawal of consent, loss to follow-up, or death (up to approximately 24 months)

Secondary outcomes

  1. Percentage of Participants Considered Improved on the Clinical Global Impression of Change (CGI-C) Scale

    The CGI-C is used to score a clinician's impression of a participant's change in global health. The CGI-C is a single item measure of change in global health, using seven response options: "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", and "very much worse". Participants considered as "improved" include responses of "very much improved, "much improved" and "minimally improved".

    Time frame: From enrollment up to the duration of the study or until withdrawal of consent, loss to follow-up, or death (up to approximately 24 months)

07

Study locations

38 sites
  • Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72103, United States
  • Loma Linda University Health Care
    Loma Linda, California 92354, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90010, United States
  • Valley Children's Hospital
    Madera, California 93636, United States
  • University California - Irvine
    Orange, California 92868, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Medstar Georgetown University Hospital
    Washington D.C., District of Columbia 20007, United States
  • Children's National Hospital
    Washington D.C., District of Columbia 20010, United States
  • Nemour's Children's Hospital, Florida
    Orlando, Florida 32827, United States
  • All Children's Research Institute, Inc.
    St. Petersburg, Florida 33701, United States
  • Advent Health Orlando
    Winter Park, Florida 32789, United States
  • Rare Disease Research, LLC
    Atlanta, Georgia 30329, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • Norton Children's Hospital
    Louisville, Kentucky 40202, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Michigan Pediatric Rehabilitation Center
    Ann Arbor, Michigan 48109, United States
  • Helen DeVos Children's Hospital at Spectrum Health
    Grand Rapids, Michigan 49503, United States
  • Gillette Children's Specialty Healthcare
    Minnetonka, Minnesota 55343, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University;Wash Uni. Sch. Of Med
    St Louis, Missouri 63110, United States
  • NYU Hospital for Joint Diseases
    New York, New York 10003, United States
  • Columbia University Med Center
    New York, New York 10032, United States
  • Cincinnati Childrens Hospital
    Cincinnati, Ohio 45229, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Childrens Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • University of Texas at Austin Health sciences, Dell Medical School
    Austin, Texas 78723, United States
  • Neurology & Neuromuscular Care Center
    Denton, Texas 76208, United States
  • Central Texas Neurology Consultants
    Round Rock, Texas 78681, United States
  • Methodist Children's Hospital of South Texas
    San Antonio, Texas 78229, United States
  • University Of Utah
    Salt Lake City, Utah 84108, United States
  • University of Virginia Children?s Hospital
    Charlottesville, Virginia 22903, United States
  • MultiCare Health System Institute for Research and Innovation
    Tacoma, Washington 98405, United States
  • UBC (Remote Coordinating Center, no physical facility)
    Morgantown, West Virginia 26508, United States
  • Childrens Hospital of Wisconsin
    Milwaukee, Wisconsin 53201, United States
  • Instituto de Rehabilitación del Caribe
    Santurce, 00912, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Oct 2026, 54 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2022
First posted
Feb 10, 2022
StartActual
Mar 29, 2022
Primary completionActual
Oct 9, 2026
CompletionActual
Oct 9, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 22, 2026
Primary completion
Oct 2, 2026→Oct 9, 2026 (actual)
Oct 22, 2026
Study completion
Oct 2, 2026→Oct 9, 2026 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Active, not recruiting→Completed
    Primary completion Oct 2, 2026→Oct 9, 2026 (now actual)
    Study completion Oct 2, 2026→Oct 9, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05232929
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Feb 10, 2022
Start date
Mar 29, 2022
Primary completion
Oct 9, 2026
Completion
Oct 9, 2026
Last update
Oct 22, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risdiplam

Start the discussion